Ulrik B. Keiding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ulrik B. Keiding has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kristian Mark Jacobsen
Department of Chemistry Aarhus University Langelandsgade 140 8000 Aarhus C Denmark
2 shared publications - Mogens Johannsen
Department of Forensic Medicine, Aarhus University, Aarhus, Denmark
2 shared publications - Thomas Bjørnskov Poulsen
Department of Chemistry, Aarhus University, Aarhus, Denmark
2 shared publications Bjørn Christiansen
Department of Chemistry, Aarhus University, 8000 Aarhus C, Denmark
1 shared publicationEsben T. Weibel
Department of Chemistry, Aarhus University, 8000 Aarhus C, Denmark
1 shared publicationEva S. Schaffert
A Chemical Biology Laboratory , Department of Chemistry , Aarhus University , DK-8000 , Aarhus C , Denmark
1 shared publication
Latest Publications
- 21 November 2016
- Published by Springer Nature in Nature Chemistry
- Vol. 9 (3) , 264-272
Synthesis of ent-BE-43547A1 reveals a potent hypoxia-selective anticancer agent and uncovers the biosynthetic origin of the APD-CLD natural products
Anti-proliferative compounds that display enhanced toxicity in a low-oxygen (hypoxic) environment may be used to eradicate aggressive and therapy-resistant cancer cells. Now, a promising lead structure has been identified in the BE-43547-class of depsipeptide natural products.
- 21 November 2016
- Published by Springer Nature in Nature Chemistry
- Vol. 9 (3) , 264-272
Synthesis of ent-BE-43547A1 reveals a potent hypoxia-selective anticancer agent and uncovers the biosynthetic origin of the APD-CLD natural products
Anti-proliferative compounds that display enhanced toxicity in a low-oxygen (hypoxic) environment may be used to eradicate aggressive and therapy-resistant cancer cells. Now, a promising lead structure has been identified in the BE-43547-class of depsipeptide natural products.
- Open Access
- 23 December 2014
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 6 (4) , 647-652
The natural product brartemicin is a high affinity ligand for the carbohydrate-recognition domain of the macrophage receptor mincle
We demonstrate that the natural product brartemicin, a newly discovered inhibitor of cancer cell invasion, is a high-affinity ligand of the carbohydrate-recognition domain (CRD) of the C-type lectin mincle. Recent studies have revealed that mincle is a key macrophage receptor for the mycobacterial virulence factor trehalose dimycolate (TDM), which is a glycolipid component of the mycobacterial cell wall. Major uncertainties, however, remain concerning the mechanism of TDM-binding and subsequent signal transduction as well as interplay of potential co-receptors. Due to the lipid nature of TDM, functional studies are difficult and soluble mincle-ligands are therefore of significant interest. Brartemicin, together with designed analogs also presented in this paper, may thus serve as useful molecular probes for future studies of mincle. Through computational studies, we further provide an insight into the probable mode of binding of brartemicin.
- 23 December 2014
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 6 (4) , 647-652
Open AccessThe natural product brartemicin is a high affinity ligand for the carbohydrate-recognition domain of the macrophage receptor mincle
We demonstrate that the natural product brartemicin, a newly discovered inhibitor of cancer cell invasion, is a high-affinity ligand of the carbohydrate-recognition domain (CRD) of the C-type lectin mincle. Recent studies have revealed that mincle is a key macrophage receptor for the mycobacterial virulence factor trehalose dimycolate (TDM), which is a glycolipid component of the mycobacterial cell wall. Major uncertainties, however, remain concerning the mechanism of TDM-binding and subsequent signal transduction as well as interplay of potential co-receptors. Due to the lipid nature of TDM, functional studies are difficult and soluble mincle-ligands are therefore of significant interest. Brartemicin, together with designed analogs also presented in this paper, may thus serve as useful molecular probes for future studies of mincle. Through computational studies, we further provide an insight into the probable mode of binding of brartemicin.